The Retina as a Chemogenetic Target for the Treatment of Depression

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1128089

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Treatments for depression are often poor because they lack selectivity. By inserting receptors that respond to an inert drug, Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) can turn on-or-off very specific classes of cells, providing an exciting treatment direction for depression and other neuropsychiatric diseases. The long term goal of this project is to create a highly effective DREADD-based treatment for depression, which is activated by either eye drops or a pill.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $408,768.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Central Nervous System

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

circadian rhythms | depression | mental health | novel therapeutic agents | retina

Related Links